Reach Us +44-3308187254


Pharmacokinetic Interaction Between Dietary Black Tea And Carbamazepine In Epileptic Patients | 13267
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Pharmacokinetic interaction between dietary black tea and carbamazepine in epileptic patients

International Summit on Clinical Pharmacy & Dispensing

S. H. Akrawi, Muna J. Hadi and Sabah Al-Dabbagh

ScientificTracks Abstracts: Clinic Pharmacol Biopharmaceut

DOI: 10.4172/2167-065X.S1.002

Black tea extract (leaves and leaf buds of the plant Camella sinensis ) consumption is generally thought to be safe and does not cause medical problem. Carbamazepine (CBZ) is used for the treatment of epileptic patients and it is extensively metabolized by liver enzymes. However, tea components (Caffeine, Theophylline, and Theobromine) induce liver enzymes; it may induce the metabolism of CBZ. Furthermore, physician should be aware regarding this interaction. The aim of this study is to predict the possibility of interactions of tea components with the disposition of Carbamazepine (CBZ) in epileptic patients. The pharmacokinetic parameters CBZ steady state serum concentrations (C SS ) and total CBZ clearances (Cl T ) were estimated. This study was conducted on thirty six epileptic patients, they were allocated into four groups, patients in group (I) and (II) were already on chronic CBZ treatment, while patients in group (III) and (IV) initiate CBZ therapy during the study. The (C SS ) for patients in group (I & III), who were tea drinker, are significantly increased after (7) days of stopping tea consumption, and (Cl T ) are significantly decreased. The (C SS ) for patients of groups (II & IV), who drunk no tea for 7 days before sampling, are significantly decreased after (7) days of drinking tea and the (ClT) are significantly increased. The total volume of tea given to the patients in each group is about (400 ml/day). According to these results epileptic patients, who are tea drinker, treated with CBZ required therapeutic drug monitoring.
Sabah Akrawi, Ph.D., graduated from the College of Pharmacy/University of Kentucky/USA. He is an assoc. Prof. of Clinical Pharmacokinetic and Biopharmaceutic and a faculty member at the College of Clinical Pharmacy/King Faisal University/KSA. He supervised 17 post graduate pharmacy students, and he has published more than 24 articles. He is a member of the scientific council of the KFU and chaired many defense committees for graduation of graduate students.